Optomed - Health technology company

Thanks for the links, interesting data. As a representative of the “average retail investor” (tuulipukusijoittaja), I really have to wonder about the company’s investor communications. WISER’s materials already contain quite concrete signs of the progress of the China venture, which Optomed itself has said very little about.

According to WISER, Optomed’s Aurora camera has NMPA approval in China. In addition, screening pilots have been launched in China, partnerships have been built with a hospital and a local AI operator, and a partnership has been established with a long-standing large optician chain. Now, Optomed’s Chinese joint venture is looking for someone to build sales for, among other things, clinics, optician shops, insurance companies, and the public sector.

If this is the path forward, then admittedly this is starting to form an interesting scenario for an investor. The regulation seems to be in order, local partners are in place, and commercial channels are being built. The Chinese model also appears broader than the U.S. model. Alongside diabetes screening, myopia as well as optician shops and primary healthcare are included. Not to mention that there are over 230 million diabetics and over 130 million people suffering from high-degree myopia in China, so the potential market is enormous.

WISER’s material is marketing-oriented, and of course, approvals, pilots, or partnerships do not yet tell us about the revenue generated for Optomed. The real value of the China case will only be determined when this activity turns into commercial volumes.

But back to investor communications. Both named partnerships started in June, i.e., in the same quarter that the August Q2 report covered. Still, it was difficult to conclude from the report that such an active commercial entity is being built in China. It is somewhat incomprehensible that those who have invested in Optomed have to piece together this kind of picture from Chinese sources. A sincere tip of the hat to the folks on the forum for their detective work.

It is also a pity that this wasn’t asked about in the CEO interview. China now looks clearly more interesting than Optomed’s own communications let on. It leaves one wondering, when will all this start to show up in Optomed’s revenue and cash flow?

13 Likes

It was offered as a topic to be asked about in the interview, and our [analyst] Kinnunen has already identified earlier that there could be more potential than previously suggested and that Inderes’ calculations might be on the conservative side. Apparently, however, China was excluded by the company from the Q2 interview, and the company will return to this when there is something more concrete to announce than just speculation.

“Binary” is still likely the right word to describe China. The big boys are whispering that Huawei will come along and copy Optomed’s camera just like that, leaving us empty-handed. I wish there was more to this joke than just speculation on this forum.

3 Likes

Copy of the article linked by @Mr_Stock.

“”“”““The director of Chongkou Street Community Health Service Center even took the initiative to ask, "Could you provide a few more machines to quickly deploy them?"””“”“”

Looks like those Aurora cameras will start moving at a good pace over there. The Chinese health boss above is asking if they could get more of those cameras quickly…:+1:

Another copy.

“”“”““Furthermore, the pilot program’s unique service model—“lightweight hardware deployment + AI quantitative empowerment + SaaS cloud service”—significantly lowers the entry barrier for primary care. It is suitable for all equipment and personnel, currently applicable to diabetic retinopathy, and can be smoothly expanded to screening for various chronic diseases””“”“”

The Chinese seem more than satisfied with this package. :+1:

19 Likes

No need to copy needlessly; H could make a takeover bid for the whole shop. At these prices, it wouldn’t cost much.

3 Likes
5 Likes

These are good points, but they’re old news being brought up now in the Optomed US LinkedIn. There’s clear awakening there (though the content and frequency are hit-or-miss), but AEYE Health and its CEO have started pumping out more and more content to the ether => three posts in two days, which is visible in the scaling follower count => now if only it would show up in dollars and customers :slight_smile:

8 Likes

Yeah, it’s an old article, but it was a response to a previous message that mentioned a 10-hour training period.

3 Likes

The Optomed USA website features a compilation of customer comments on using the Aurora camera in actual patient care. These are worth reading as they are based on real-world experience. Mentions of high image quality and ease of use, among other things, recur in these testimonials.

I would also like to add that the aforementioned comments refer to the Aurora camera. Lumo is even easier to learn to use, easier to use in patient care, and has better image quality than Aurora.

16 Likes

Interesting… haven’t there been user experiences appearing here that didn’t exist previously, for example that one about Utah?

Jeez… sorry. I didn’t realize that context. My bad…

1 Like

https://www.redeye.se/research/1180791/optomed-strong-h2-ahead

14 Likes

Now there’s finally some commentary on what was left out of the Inderes interview. BF is ready at the starting blocks, all the documents are ready, and the business plan is being polished. This is a binary case as well. As for the China JV, trials are underway and Wiser is handling the commentary; this is binary too.

Why on earth couldn’t this have been communicated sooner? It’s hard to make sense of this, but it’s good that things are happening under the surface.

12 Likes

So the missing piece with Big Pharma has been handled. Great.

15 Likes

I listened to the Redeye interview. A Big Pharma partnership would also require investments from Optomed, and the revenue/returns are a long-term prospect. Everything is ready, but it is being considered.

It doesn’t seem like Optomed is currently able to invest in that. The cash position must be protected.

5 Likes

It’s also possible that they are hitting a wall with resources other than cash; specifically, if the focus is on the USA and Aurora AEYE and the pull is strong enough, freeing up human resources for this could potentially be a bottleneck.

This deal with Big Pharma / AZ is invaluable to Optomed. Thanks to it, Optomed’s BRAND VALUE globally will rise to a whole new level, and this will facilitate all other business.

Waiting for the news on the deal…

14 Likes

There are many ways to interpret that. If you look at Himberg’s body language, things are cooking in the oven and moving forward. I wouldn’t be worried at all; it will definitely come through.

16 Likes

Yeah, I’m not worried either. But it’s probably best not to expect anything regarding that matter this year.

3 Likes

That “product archives” page is still haunting Optomed’s website, and as far as I can tell, it has incorrect information regarding the current price of $4,500 for 3 months. You can find it on the interwebs by searching for “aurora AEYE price,” and I can imagine many people looking directly at that link for the pricing. If anyone wants to notify Optomed about it :smiley:

Isn’t that the price… of course, the more the better if sales are going well, but that’s the number I remember as well. $1500/month, so $18,000 a year